A congenital generalized lipodystrophy patient complicated with critical central neurological involvement due to BSCL2 mutations

Abstract

Abstract: Objective To retrospectively analyze the clinical data of a patient with congenital generalized lipodystrophy (CGL) type 2 caused by BSCL2 mutation. Methods The clinical data of a patient with CGL was analyzed, including clinical features, laboratory data. The next generation sequencing was adopted to inspect gene mutations associated with CGL. Sanger sequencing was used to verify the pathogenic mutations. Treatment and follow-up were given to the patient. Results Patient manifested as lacking of subcutaneous fat,hepatomegaly,acanthosis nigricans,developmental retardation,epilepsy,ataxia and neurodegeneration. The levels of serum liver enzyme, triacylglyceride(TAG) and fasting insulin increased. Multiple types of seizures were detected by electroencephalogram (EEG). Gene sequencing revealed homozygous mutations of BSCL2,c.782dupG inherited from his parents respectively. The patient failed to respond to the treatment with diet control, metformin and lamotrigine, and neurologic function deteriorated gradually. Conclusions CGL2 caused by BSCL2 base repeat mutation may have serious and lethal nervous degeneration in addition to typical lipodystrophy.

Key words: congenital generalized lipodystrophy, caused by BSCL2, sepin, epilepsy

CLC Number:

R748

DING Juan,MA Ming-sheng,QIU Zheng-qing. A congenital generalized lipodystrophy patient complicated with critical central neurological involvement due to BSCL2 mutations[J]. Basic & Clinical Medicine, 2021, 41(9): 1333-1337.

References

[1]Berardinelli, W. An undiagnosed endocrinometabolic syndrome: report of two cases[J]. Clin Endocrinol Metab,1954,14:193-204.
[2]Magré J, Delépine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13[J]. Nat Genet, 2001,28:365-370.
[3]Van Maldergem L, Magré J, Khallouf TE, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy[J]. J Med Genet,2002,39:722-733.
[4]李辉,季成叶,宗心南, 等.中国0～18岁儿童、青少年身高、体重的标准化生长曲线[J].中华儿科杂志,2009,47:487-492.
[5]Guillen-Navarro E, Sanchez-Iglesias S , Domingo-Jimenez R , et al. A new seipin-associated neurodegenerative syndrome[J]. J Med Genet, 2013, 50:401-409.
[6]Opri R, Fabrizi GM, Cantalupo G, et al. Progressive myoclonus epilepsy in congenital generalized lipodystrophy type 2: report of 3 cases and literature review[J]. Seizure, 2016,42:1-6.
[7]Sánchez-Iglesias S, Crocker M, O'Callaghan M, et al. Celia's encephalopathy and c.974dupG in BSCL2 gene: a hidden change in a known variant[J]. Neurogenetics, 2019,20:73-82.
[8]Alaei MR, Talebi S, Ghofrani M, et al. Whole exome sequencing reveals a BSCL2 mutation causing progressive encephalopathy with lipodystrophy (PELD) in an Iranian pediatric patient[J]. Iran Biomed J,2016,20:295-301.
[9]Zhang Y, Chen X, Luo F, et al. Medical management of a child with congenital generalized lipodystrophy accompanied with progressive myoclonic epilepsy: a case report[J]. Medicine (Baltimore),2019,98:e18121. doi:10.1097/MD.0000000000018121
[10]Ruiz-Riquelme A, Sánchez-Iglesias S, Rábano A, et al. Larger aggregates of mutant seipin in Celia's Encephalopathy, a new protein misfolding neurodegenerative disease[J]. Neurobiol Dis, 2015,83:44-53.
[11]Serino D, Davico C, Specchio N, et al. Berardinelli-Seip syndrome and progressive myoclonus epilepsy[J]. Epileptic Disord,2019,21:117-121.
[12]Araújo-Vilar D, Domingo-Jiménez R, Ruibal Á, et al. Association of metreleptin treatment and dietary interven-tion with neurological outcomes in Celia’s encephalopathy[J]. Eur J Hum Genet, 2018, 26:396-406.